Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis

US7368421B2 · kind B2 · utility

Assignee

• PROBIODRUG AG · DE

Inventors

• Hans-Ulrich Demuth · Halle (Saale), DE
• Torsten Hoffmann · Weil am Rhein, DE
• Konrad Glund · Halle (Saale), DE
• Ulrich Heiser · Halle (Saale), DE
• Stephan von Hoersten · Großburgwedel, DE

Key dates

• Filing date: Apr 19, 2002
• Grant date: May 6, 2008
• Expiry date: Aug 18, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K5/0812
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a new use of DP IV-inhibitors. The compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful in treating conditions mediated by DP IV or DP IV-like enzymes, such as immune, autoimmune or central nervous system disorder selected from the group consisting of strokes, tumors, ischemia, Parkinson's disease and migraines. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of multiple sclerosis.